Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Cédric Rossi et al.|Blood Advances|2021Cited by 51
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Alina Berriolo-Riedinger et al.|Blood|2020Cited by 3
Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Tommi Salmi et al.|Blood Advances|2025Cited by 2
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell LymphomaJuliette Pénichoux, Vincent Camus, Pierre Decazes et al.|Hematological Oncology|2025Cited by 1